Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Arquitos Capital Management Steven Kiel | “Finch is executing a strategic Chapter 11 filing to shed lease liabilities and execute a full sale of its assets, including valuable patents and major ongoing litigation claims. The manager believes this orderly process will successfully maximize shareholder returns and yield a significant premium above their purchase price.” | BULL | Q1 2026 Apr 30, 2026 | View Pitch |
Arquitos Capital Management Steven Kiel | “Finch's share price rose to $12.28 at the end of the third quarter, up from $11.30 at the start of the year. As a reminder, Finch won a jury trial in August 2024 against Ferring Pharmaceuticals, with the jury finding that Ferring infringed three of Finch's patents. The verdict awarded Finch approximately $30 million in a one-time licensing fee and pre-trial interest, plus ongoing royalties to be determined by the judge and post-trial interest. Importantly, the jury also found willful infringement, opening the door for enhanced damages up to three times the jury award. When I first discussed Finch in January, I had expected a post-trial decision by the end of the first quarter. That obviously hasn't happened yet, but the potential outcome makes the wait worthwhile. Even under the worst-case scenario, without any enhanced damages, Finch shares are worth at least double their current price. I won't speculate further on timing. What I can say is that this is a situation worth waiting for, and we are content to do so. BSD Analysis: This is a legal-process catalyst with asymmetric payoff: a $30M base award plus ongoing royalties already secured by jury verdict, with willfulness enabling potential trebling. Timing slippage is the main risk, but even the manager's “no-enhancement” downside implies >2x valuation upside. Liquidity and cash runway should be monitored; proceeds could fund pipeline or shareholder returns. A final judgment and royalty rate determination are the inflection points; any settlement could accelerate value realization.” | BULL | Q3 2025 Oct 20, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
